Deep Intelligence Across Industries

STERIS is one of the world's largest specialists in infection prevention and sterilisation. It sells the consumables, capital equipment and services that hospitals and medical-device and pharmaceutical manufacturers use to clean, disinfect and sterilise instruments, devices and controlled environments. The group runs three segments. Healthcare (71% of FY2026 revenue) supplies hospital sterile-processing departments, operating rooms and endoscopy suites. Applied Sterilization Technologies (AST, 19%) is a technology-neutral contract sterilisation and testing network of more than 60 facilities using gamma, ethylene oxide (EO), electron-beam and X-ray. Life Sciences (10%) supplies pharmaceutical and biotech manufacturers with cleanroom chemistries, sterility assurance products, sterilisers, washers and vaporised hydrogen peroxide (VHP) biodecontamination systems. About 79% of revenue is recurring consumables and service, and 73% is earned in the United States. FY2026 revenue was $5.94 billion, with an adjusted operating margin of 23.3% and $983 million of free cash flow. That cash funds a dividend raised for 21 straight years, a $1 billion buyback authorisation, and the pending $2.1 billion debt-financed purchase of Xodus Medical. --- ### What the company does In its annual report, STERIS describes itself as a leading global provider of products and services that support patient care with an emphasis on infection prevention. Its stated mission is "WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences products and services." Products include cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, instruments, washers, sterilisers and other capital equipment. These are essential to a hospital sterile processing department and to the procedural areas it serves (operating rooms, ambulatory surgery centres and endoscopy suites). Alongside the products, STERIS offers equipment maintenance, instrument repair, off-site reprocessing and contract sterilisation and laboratory services. ### Business model and revenue model | Revenue type, FY2026 | USD M | % of total | Characteristics | |---|---|---|---| | Service | 2,875.8 | 48.4 | Preventive maintenance and repair contracts, instrument repair, off-site reprocessing, AST contract sterilisation, laboratory testing | | Consumables | 1,808.4 | 30.5 | Detergents, disinfectants, sterilants, sterility assurance indicators, endoscopy accessories, procedural and instrument-care disposables | | Capital equipment | 1,251.7 | 21.1 | Sterilisers, washer-disinfectors, surgical tables and lights, OR integration, endoscope reprocessors, pharma sterilisers and VHP systems | | Recurring (service + consumables) | 4,684.2 | 78.9 | — | | Total | 5,935.9 | 100.0 | — | STERIS uses a razor/razor-blade model, extended by a large service franchise. **Service:** USD M: 2,875.8; % of total: 48.4; Characteristics: Preventive maintenance and repair contracts, instrument repair, off-site reprocessing, AST contract sterilisation, laboratory testing **Consumables:** USD M: 1,808.4; % of total: 30.5; Characteristics: Detergents, disinfectants, sterilants, sterility assurance indicators, endoscopy accessories, procedural and instrument-care disposables **Capital equipment:** USD M: 1,251.7; % of total: 21.1; Characteristics: Sterilisers, washer-disinfectors, surgical tables and lights, OR integration, endoscope reprocessors, pharma sterilisers and VHP systems - ****Recurring (service + consumables)** — USD M: 4,684.2; % of total: 78.9 - Total — USD M: 5,935.9; % of total: 100.0 Revenue comes from product and service sales. STERIS does not report a subscription or software-licensing line, although service contracts are typically annual or multi-year. Each installed piece of capital equipment pulls through consumables (chemistries and sterility indicators) and service contracts. AST is a pure service business priced per cubic foot or per pallet processed, usually under multi-year supply agreements with device manufacturers. ### Value-chain position STERIS sits in the middle of the infection-prevention value chain. Upstream, it buys stainless steel, electronics, specialty chemicals, ethylene oxide and cobalt-60 (single-sourced, chiefly from Nordion, a unit of competitor Sotera Health). It manufactures equipment and formulated chemistries in-house. Downstream, it sells directly and through dealers and distributors to hospitals, ambulatory surgery centres, device manufacturers and pharmaceutical plants. In AST it is an outsourced processing step in the medical-device manufacturing chain. STERIS has formulated-chemistry and contamination-control product lines (Healthcare and Life Sciences combined generate more than $700 million of formulated-chemistries revenue), and some of these serve controlled-environment industries such as semiconductor fabrication. However, the company does not report semiconductors as a separate end market, and its cleanroom business is overwhelmingly tied to pharmaceutical and biotech aseptic manufacturing. ### Customer types and end-markets | End-market | Segment | Customers | Demand driver | |---|---|---|---| | Acute-care hospitals and ambulatory surgery centres | Healthcare | Sterile processing departments, OR managers, endoscopy suites, GI labs | Surgical and GI procedure volumes, hospital capex budgets, regulatory compliance (AAMI, Joint Commission) | | Medical-device manufacturers | AST | OEMs and contract manufacturers of single-use devices, implants and kits | Device unit volumes, outsourcing of terminal sterilisation, EO capacity constraints | | Pharmaceutical and biopharmaceutical manufacturing | Life Sciences | Aseptic fill-finish plants, biologics plants, compounding pharmacies, research labs | Cleanroom build-outs, GMP compliance (EU Annex 1, FDA), biologics capacity | | Other controlled environments | Life Sciences (minor) | Laboratories and other critical-environment operators | Contamination-control standards | Acute-care hospitals and ambulatory surgery centres: Segment: Healthcare; Customers: Sterile processing departments, OR managers, endoscopy suites, GI labs; Demand driver: Surgical and GI procedure volumes, hospital capex budgets, regulatory compliance (AAMI, Joint Commission) Medical-device manufacturers: Segment: AST; Customers: OEMs and contract manufacturers of single-use devices, implants and kits; Demand driver: Device unit volumes, outsourcing of terminal sterilisation, EO capacity constraints Pharmaceutical and biopharmaceutical manufacturing: Segment: Life Sciences; Customers: Aseptic fill-finish plants, biologics plants, compounding pharmacies, research labs; Demand driver: Cleanroom build-outs, GMP compliance (EU Annex 1, FDA), biologics capacity Other controlled environments:** Segment: Life Sciences (minor); Customers: Laboratories and other critical-environment operators; Demand driver: Contamination-control standards ### Independent characterisation STERIS has become a consumables-and-service compounder. Since FY2022, about four-fifths of revenue has been recurring. Its two competitive moats are an installed base of hospital sterile-processing equipment that is hard to displace, and an AST network whose regulatory permits (especially for EO) are expensive and slow to replicate. The 2021 Cantel acquisition, the 2024 sale of Dental and the pending Xodus deal have pushed the portfolio further toward high-margin procedural consumables. The main structural exposures are U.S. hospital capital cycles, EO regulation and litigation, and destocking cycles among device customers in AST.